Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi

• Päätekijät: Sundos Khan (Tekijä), Matthew Parrillo (Tekijä), Andres H. Gutierrez (Tekijä), Frances E. Terry (Tekijä), Leonard Moise (Tekijä), William D. Martin (Tekijä), Anne S. De Groot (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Taylor & Francis Group, 2020-02-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

The RTS,S/AS01 malaria vaccine will undergo a pilot vaccination study in sub-Saharan Africa beginning in 2019. RTS,S/AS01 Phase III trials reported an efficacy of 28.3% (children 5-17 months) and 18.3% (infants 6-12 weeks), with substantial variability across study sites. We postulated that the rela...